CKConnie A. Keehn

Connie A. Keehn

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Connie A. Keehn has a total of 11 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Marginal zone lymphoma with a dual cutaneous and leukemic presentation and an aberrant myeloid‐monocytic phenotype

    by Connie A Keehn, Hernani Cualing

    Marginal zone lymphoma (MZL) is an indolent neoplasm of mature B cells, classified by the World Health Organization into three categories: nodal, splenic, and extranodal MZL of mucosa-associated lymphoid tissue (MALT lymphoma). We present an unusual case of MZL with cutaneous, leukemic, and bone marrow involvement at presentation and expression of an aberrant myeloid-monocytic phenotype. This case is best classified as MZL of leukemic subtype.


  • PLEXIFORM NEUROFIBROMA IN TYPE 1 NEUROFIBROMATOSIS

    by Connie A. Keehn, Pearl Myers, Charles N. Paidas, Enid Gilbert-Barness

    A 13-year-old African-American girl was admitted to the hospital for surgery. She was diagnosed with Type I neurofibromatosis at the age of 1 year after she was noted to have multiple café au lait spots. Her past medical history included a history of neurofibroma in the base of the brain, treated with radiation therapy and ventriculoperitoneal shunt, as well as a recent diagnosis of bilateral optic gliomas, treated with chemotherapy. Family history was negative for neurofibromatosis.


  • Cutaneous metastasis: a clinical, pathological, and immunohistochemical appraisal

    by Sadia Saeed, Connie A. Keehn, Michael B. Morgan

    Background:  Cutaneous tumor metastasis may be the first manifestation of cancer, but more often is a harbinger of advanced disease that portends an ominous prognosis. All skin accessions over the past 10 years from a large Veterans Administration (VA) hospital were reviewed.Methods:  Archived histories, glass slides, and the immunohistochemical battery (IHC), were assessed to determine diagnostic accuracy.Results:  Of the 100,453 cases reviewed, there were a total of 77 cases (75 males and 2 females) of cutaneous metastasis from the lungs (28.6%), metastatic melanoma (18.2%), gastrointestinal tract (14.2%), genitourinary tract (10.4%), head and neck (9.1%), hematologic (5.2%), breast (5.2%), and miscellaneous (Conclusions:  Excluding the potential for age and gender bias in this study conducted in a VA setting, cutaneous metastases represent an uncommon, deadly, and late‐developing occurrence in many patients. Compared with previous studies, lung carcinoma remains the most common of the cutaneous metastases, with a relative rise in the incidence of metastatic melanoma. The immunohistochemical battery of CK‐7, CK‐20, and S‐100 is a helpful adjunct in narrowing the differential diagnosis of the primary site of a large proportion of cutaneous metastases, particularly tumors with an epithelioid appearance such as carcinomas and melanomas.


  • Expression of insulin‐like growth factor‐I receptor in primary cutaneous carcinomas

    by Connie A. Keehn, Sadia Saeed, Kelly Bickle, Farah K. Khalil, Michael B. Morgan

    Insulin-like growth factor-I (IGF-I) is the principal mediator of growth hormone, exerting its effects through binding of the insulin-like growth factor-I receptor (IGF-IR). Post-receptor activation leads to the production of transcription factors involved in cell proliferation, differentiation, transformation, and survival. Data indicate that IGF-IR is involved in tumorigenesis. To our knowledge, this receptor has not been previously studied in primary cutaneous carcinomas. Twenty-five cases of primary cutaneous carcinomas consisting of three keratoacanthoma-type squamous cell carcinomas (KAs), two squamous cell carcinomas in situ (SCCs in situ), eight squamous cell carcinomas (SCCs), three conventional basal cell carcinomas (BCCs), two morpheaform basal cell carcinomas (M-BCCs), and seven Merkel cell carcinomas (MCCs) were analyzed for IGF-IR immunohistochemical expression using IGF-IR mouse monoclonal antibody (dilution 1 : 50) using the avidin-biotin-peroxidase complex method. Normal epidermis was negative for IGF-IR expression. Normal eccrine glands and outer root sheath strongly expressed IGF-IR. All KAs, SCCs in situ, SCCs, and BCCs were negative for IGF-IR expression. Six of seven (86%) of the MCCs stained with IGF-IR strongly, showing cell membrane accentuation and a perinuclear dot-like pattern. The data suggest that IGF-IR immunopositivity in MCCs might constitute a diagnostic tool in discriminating between SCCs and BCCs. Although the possible pathogenic significance of the perinuclear dot-like staining pattern observed in these neoplasms is unknown, its pattern is similar to what has been previously described with cytokeratin-20 immunostaining.


  • Hamartin and tuberin immunohistochemical expression in cutaneous fibroepithelial polyps

    by Jamie Wu, Farah K. Khalil, Connie A. Keehn, Sadia Saeed, Michael B. Morgan

    Background:  Hamartin and tuberin are inactivating tumor suppressor proteins implicated in the development of gastrointestinal polyps and sporadic and tuberous sclerosis‐associated cutaneous angiofibromas. The pattern of expression of these peptides has not been studied in fibroepithelial polyps (FEPs).Design:  The specific aim of the study was to evaluate the immunohistochemical expression of tuberin and hamartin within the epithelium and dermal fibrocytes of 20 cutaneous FEPs compared with the epithelium and dermal fibrocytes of normal skin. The diagnoses were confirmed independently by a dermatopathologist, and the pattern of intensity was assessed by the mean labeling intensity (MLI) of cytoplasmic and/or nuclear staining for each antibody.Results:  Hamartin and tuberin antibodies showed moderate staining of the keratinocytes and fibrocytes of normal skin and the keratinocytes within FEPs. Both antibodies showed diminished staining within the fibrocytes of the FEPs. The MLI of hamartin was 44.3 ± 4.4 for keratinocyte nuclei in normal skin and 51.2 ± 3.7 within the polyps. The MLI of tuberin was 42.9 ± 3.6 within the keratinocyte nuclei of the normal skin compared to 39.7 ± 3.0 for the polyps. The MLI for hamartin within the fibrocytes of the normal skin was 78.9 ± 7.1 compared to 21.6 ± 4.2 within the polyps, p = 0.01. The MLI for tuberin within the fibrocytes of normal skin was 70.6 ± 5.0 compared to 47.1 ± 4.7 within the polyps.Conclusion:  The data suggest that down regulation or loss of tuberin and/or hamartin expression may be permissive to fibrocyte proliferation or promote collagen production leading to FEP formation.


  • Open Access

    Expression of the Ets-1 Proto-Oncogene in Melanocytic Lesions

    by Connie A Keehn, Bruce R Smoller, Michael B Morgan